{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:00:47Z","timestamp":1790236847444,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We examined the association between blood pressure (BP) time in target range and clinical outcomes in chronic kidney disease (CKD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In 1908 participants in the Chronic Renal Insufficiency Cohort study who had BP measured at each visit for the first 5 years of the study, BP time in target range was defined as the percentage of visits with BP &amp;lt;130\/80 mm\u00a0Hg between baseline and year 5; and categorized into 3 groups (&amp;lt;25%, 25%-75% and &amp;gt;75% of visits in target). Outcomes included cardiovascular events, kidney outcomes, and mortality occurring after the year 5 visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>BP was in target range &amp;lt;25% of visits in 430 (22.5%) participants; 909 (47.6%) participants had BP in target range 25%-75% of visits, and 569 (29.8%) participants had BP in target range &amp;gt;75% of visits. Participants with BP in target range at &amp;lt;25% of visits had higher risks of subsequent cardiovascular events (hazard ratio [HR] 1.76, 95% confidence intervals 1.28-2.41), kidney outcomes (HR 2.25, 1.66-3.05), and all-cause mortality (HR 1.54, 1.21-1.97) compared with those controlled at &amp;gt;75% of visits Participants with BP in target range at 25%-75% of visits had higher risks of subsequent cardiovascular events (HR 1.46, 1.12-1.89), and kidney outcomes (HR 1.55, 1.21-1.98), compared with those controlled at &amp;gt;75% of visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Participants with CKD with lower BP time in target range over a 5-year period had a higher risk of subsequent renal and cardiovascular outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajh\/hpag085","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:39:12Z","timestamp":1786448352000},"source":"Crossref","is-referenced-by-count":0,"title":["Blood pressure time in target range and clinical outcomes in chronic kidney disease"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9025-7413","authenticated-orcid":false,"given":"Mahboob","family":"Rahman","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo'tasem","family":"Dweekat","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-7041","authenticated-orcid":false,"given":"Ming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2026092403364206100_hpag085-B1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","article-title":"Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int."},{"key":"2026092403364206100_hpag085-B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fmed.2025.1630160","article-title":"Management of hypertension in chronic kidney disease: current perspectives and therapeutic strategies","volume":"12","author":"Alsalloum","year":"2025","journal-title":"Front Med."},{"key":"2026092403364206100_hpag085-B3","volume-title":"Hypertension Prevalence, Awareness, Treatment, and Control Among Adults Age 18 and Older: United States, August 2021-August 2023","author":"Fryar","year":"2024"},{"key":"2026092403364206100_hpag085-B4","year":"2023"},{"key":"2026092403364206100_hpag085-B5","author":"United States Renal Data System","year":"2022"},{"key":"2026092403364206100_hpag085-B6","volume-title":"Proposed New Measure for HEDIS\u00ae MY 2025: Blood Pressure Control for Patients With Hypertension (BPC-E)","author":"National Committee for Quality Assurance","year":"2024"},{"key":"2026092403364206100_hpag085-B7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/HYPERTENSIONAHA.124.24013","article-title":"Time in target range for blood pressure and adverse health outcomes: a systematic review","volume":"82","author":"Wang","year":"2025","journal-title":"Hypertension."},{"key":"2026092403364206100_hpag085-B8","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/ajh\/hpaf141","article-title":"The impact of time-in-target range for systolic blood pressure on left ventricular hypertrophy","volume":"38","author":"Wang","year":"2025","journal-title":"Am J Hypertens."},{"key":"2026092403364206100_hpag085-B9","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1161\/HYPERTENSIONAHA.125.25511","article-title":"Systolic blood pressure time in target range and acute kidney injury in patients with hypertension","volume":"82","author":"Chen","year":"2025","journal-title":"Hypertension."},{"key":"2026092403364206100_hpag085-B10","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2021.01.014","article-title":"Range and cardiovascular outcomes in patients with hypertension","volume":"77","author":"Fatani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026092403364206100_hpag085-B11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1161\/HYPERTENSIONAHA.122.20711","article-title":"Systolic blood pressure time in target range and cognitive outcomes: insights from the SPRINT MIND trial","volume":"80","author":"Li","year":"2023","journal-title":"Hypertension."},{"key":"2026092403364206100_hpag085-B12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000546380","article-title":"Time in target range of systolic blood pressure and cardiovascular disease in patients with chronic kidney disease: a Korean nationwide cohort study","volume":"57","author":"Yoon","year":"2026","journal-title":"Am J Nephrol"},{"key":"2026092403364206100_hpag085-B13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12882-015-0085-6","article-title":"Association between 24-hour blood pressure variability and chronic kidney disease: a cross-sectional analysis of African Americans participating in the Jackson Heart Study","volume":"16","author":"Tanner","year":"2015","journal-title":"BMC Nephrol."},{"key":"2026092403364206100_hpag085-B14","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1681\/ASN.2020030236","article-title":"Prognostic significance of ambulatory BP monitoring in CKD: a report from the chronic renal insufficiency cohort (CRIC) study","volume":"31","author":"Rahman","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026092403364206100_hpag085-B15","doi-asserted-by":"publisher","first-page":"S148","DOI":"10.1097\/01.asn.0000070149.78399.ce","article-title":"The chronic renal insufficiency cohort (CRIC) study: design and methods","volume":"14","author":"Feldman","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2026092403364206100_hpag085-B16","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.2215\/CJN.00070109","article-title":"Chronic renal insufficiency cohort (CRIC) Study: baseline characteristics and associations with kidney function","volume":"4","author":"Lash","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026092403364206100_hpag085-B17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1053\/j.ajkd.2012.04.012","article-title":"Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) study","volume":"60","author":"Anderson","year":"2012","journal-title":"Am J Kidney Dis."},{"key":"2026092403364206100_hpag085-B18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.ajkd.2014.07.025","article-title":"Urine neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease and death in CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) study","volume":"65","author":"Liu","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2026092403364206100_hpag085-B19","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026092403364206100_hpag085-B20","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1093\/eurheartj\/ehaf659","article-title":"Correction to: 2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the Task Force on the Management of Elevated Blood Pressure and Hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)","volume":"46","author":"European Society of Cardiology Task Force on the Management of Elevated Blood Pressure and Hypertension","year":"2025","journal-title":"Eur Heart J"},{"key":"2026092403364206100_hpag085-B21","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026092403364206100_hpag085-B22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1053\/j.ajkd.2007.09.023","article-title":"Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP)","volume":"51","author":"Duru","year":"2008","journal-title":"Am J Kidney Dis."},{"key":"2026092403364206100_hpag085-B23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1053\/j.ajkd.2009.09.014","article-title":"Hypertension awareness, treatment, and control in adults with CKD: results from the chronic renal insufficiency cohort (CRIC) study","volume":"55","author":"Muntner","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2026092403364206100_hpag085-B24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11886-022-01826-x","article-title":"Racial and ethnic disparities in hypertension: barriers and opportunities to improve blood pressure control","volume":"25","author":"Abrahamowicz","year":"2023","journal-title":"Curr Cardiol Rep."},{"key":"2026092403364206100_hpag085-B25","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease\u2014results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"2026092403364206100_hpag085-B26","volume-title":"The Surgeon General\u2019s Call to Action to Control Hypertension","author":"Substance Abuse and Mental Health Services Administration (US); Office of the Surgeon General (US)","year":"2020"},{"key":"2026092403364206100_hpag085-B27","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s11886-024-02111-9","article-title":"Blood pressure time in target range and its impact on clinical outcomes","volume":"26","author":"Al-Dalakta","year":"2024","journal-title":"Curr Cardiol Rep."},{"key":"2026092403364206100_hpag085-B28","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.kint.2023.12.008","article-title":"Findings from the KNOW-CKD study indicate that higher systolic blood pressure time in target range is associated with a lower risk of chronic kidney disease progression","volume":"105","author":"Park","year":"2024","journal-title":"Kidney Int"},{"key":"2026092403364206100_hpag085-B29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1161\/HYPERTENSIONAHA.122.20141","article-title":"Systolic blood pressure time in target range and major adverse kidney and cardiovascular events","volume":"80","author":"Buckley","year":"2023","journal-title":"Hypertension."},{"key":"2026092403364206100_hpag085-B30","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/s41440-025-02173-4","article-title":"Time in target range of systolic blood pressure and eGFR slope in patients with type 2 diabetes","volume":"48","author":"Cheng","year":"2025","journal-title":"Hypertens Res."},{"key":"2026092403364206100_hpag085-B31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jacadv.2025.101702","article-title":"Long-term systolic blood pressure time in target range and cardiovascular disease in individuals with hypertension","volume":"4","author":"Huo","year":"2025","journal-title":"JACC Adv"},{"key":"2026092403364206100_hpag085-B32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/ajh\/hpae144","article-title":"Time in target range, all-cause mortality, and cardiovascular diseases","volume":"38","author":"Wu","year":"2025","journal-title":"Am J Hypertens."},{"key":"2026092403364206100_hpag085-B33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jchf.2022.01.010","article-title":"Prognostic value of time in blood pressure target range among patients with heart failure","volume":"10","author":"Chen","year":"2022","journal-title":"JACC Heart Fail"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpag085\/70609385\/hpag085.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpag085\/70609385\/hpag085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:36:48Z","timestamp":1790235408000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article\/doi\/10.1093\/ajh\/hpag085\/8758880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":33,"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpag085","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"hpag085"}}